The vitamin D-antimicrobial peptide pathway and its role in protection against infection

Future Microbiology

Volumn 4, Issue 9, 2009, Pages 1151-1165

  Gombart, Adrian F ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial peptide; Bile acid; Cathelicidin; Infection; Innate immunity; Intestinal; Steroid hormone receptor; Vitamin D; Vitamin D receptor; Xenobiotic

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; B7 ANTIGEN; BETA DEFENSIN 4; BILE ACID; BUTYRIC ACID; CALCIFEDIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD40 ANTIGEN; CD86 ANTIGEN; COD LIVER OIL; COLECALCIFEROL; ERGOCALCIFEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; MACROPHAGE DERIVED CHEMOKINE; PLACEBO; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; UNINDEXED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BACTERIAL GENE; BACTERIAL INFECTION; BURN INFECTION; CLINICAL TRIAL; DIET THERAPY; DRUG EFFICACY; GENE CONTROL; GENE EXPRESSION REGULATION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION PREVENTION; INFECTION RATE; INFLUENZA; INNATE IMMUNITY; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; SEPSIS; SHIGELLOSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUBERCULOSIS; VAGINITIS; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; METABOLIC NETWORKS AND PATHWAYS; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 73649137170     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.87     Document Type: Review

References (129)

1. Bikle D: Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 94 (1), 26-34 (2009).
2. Holick MF, Chen TC: Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87 (4), 1080S-1086S (2008).
3. Mangelsdorf DJ, Thummel C, Beato M et al.: The nuclear receptor superfamily: the second decade. Cell 83 (6), 835-839 (1995).
4. 3. Biochem. J. 316 (Pt 2), 361-371 (1996).
5. Bouillon R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C: Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. Eur. J. Endocrinol. 133 (1), 7-16 (1995).
6. James SY, Williams MA, Newland AC, Colston KW: Leukemia cell differentiation cellular and molecular interactions of retinoids and vitamin D. Gen. Pharmacol. 32 (1), 143-154 (1999).
7. Zierold C, Darwish HM, Deluca HF: Two vitamin D response elements function in the rat 1, 25-dihydroxyvitamin D 24-hydroxylase promoter. J. Biol. Chem. 270 (4), 1675-1678 (1995).
8. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M: Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1, 25-dihydroxyvitamin D synthesis.J. Biol. Chem. 280 (21), 20604-20611 (2005).
9. 3 receptors in human leukocytes. Science 221 (4616), 1181-1183 (1983).
10. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 57 (6), 1308-1310 (1983).
11. Deluca HF, Cantorna MT: Vitamin D: its role and uses in immunology. FASEB J. 15 (14), 2579-2585 (2001).
12. Adorini L, Giarratana N, Penna G: Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 16 (2), 127-134 (2004).
13. 3: preferential inhibition of Th1 functions. J. Nutr. 125 (Suppl. 6), 1704S-1708S (1995).
14. + T cells to enhance the development of Th2 cells. J. Immunol. 167 (9), 4974-4980 (2001).
15. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164 (5), 2405-2411 (2000).
16. + T cells. J. Immunol. 168 (3), 1181-1189 (2002).
17. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM: Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1JTh17 to a Th2 and regulatory Tcell profile. J. Pharmacol. Exp. Ther. 324 (1), 23-33 (2008).
18. Adorini L, Penna G: Dendritic cell tolerogenicity in immunomodulation by vitamin D receptor agonists. Hum. Immunol. (2009) (Epub ahead of print).
19. Adorini L, Penna G: Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70 (5), 345-352 (2009).
20. Adorini L, Penna G, Giarratana N et al.: Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands.J. Steroid Biochem. Mol. Biol. 89-90 (1-5), 437-441 (2004).
21. Adorini L: Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 233 (2), 115-124 (2005).
22. Mathieu C, Adorini L: The coming of age of 1, 25-dihydroxyvitamin D (3) analogs as immunomodulatory agents. Trends Mol. Med. 8 (4), 174-179 (2002).
23. Adorini L, Penna G: Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4 (8), 404-412 (2008).
24. 3 on human B cell differentiation. J. Immunol. 179 (3), 1634-1647 (2007).
25. Liu PT, Stenger S, Li H et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (5768), 1770-1773 (2006).
26. 3 induces an autoantigen-specific T-helper 1JT-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49 (8), 1301-1307 (2000).
27. 3 by normal human macrophages. Biochem. Biophys. Res. Commun. 127 (2), 596-603 (1985).
28. Hewison M, Kantorovich V, Liker HR et al.: Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J. Bone Miner. Res. 18 (3), 579-582 (2003).
29. 3 by cells recovered by bronchoalveolar lavage and the role of this metabolite in calcium homeostasis. Am. Rev. Respir. Dis. 138 (4), 984-989 (1988).
30. 3 by interferon-γ-stimulated normal human bone marrow and alveolar macrophages. J. Biol. Chem. 262 (23), 10931-10937 (1987).
31. 3. Proc. NatlAcad. Sci. USA 92 (24), 10990-10994 (1995).
32. 3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-κbmediated interleukin-8 gene expression. Eur. J. Biochem. 250 (1), 63-71 (1997).
33. Sun J, Kong J, Duan Y et al.: Increased NF-κb activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol Endocrinol Metab. 291 (2), E315-E322 (2006).
34. 3: basic concepts. J. Steroid Biochem. Mol. Biol. 97 (1-2), 93-101 (2005).
35. 3 induces splenocyte apoptosis and enhances BALB/C mice sensitivity to toxoplasmosis. J. Steroid Biochem. Mol. Biol. 96 (2), 179-185 (2005).
36. Ehrchen J, Helming L, Varga G et al.: Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. FASEB J. 21 (12), 3208-3218 (2007).
37. Martineau AR, Wilkinson KA, Newton SM et al.: IFN-γ-and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol. 178 (11), 7190-7198 (2007).
38. 3. FASEB J. 19 (9), 1067-1077 (2005).
39. 3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173 (5), 2909-2912 (2004).
40. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma H, Stahle M: Vitamin D induces the antimicrobial protein hCAP18 in human skin. J. Invest. Dermatol. 124 (5), 1080-1082 (2005).
41. Zasloff M: Fighting infections with vitamin D. Nat. Med. 12 (4), 388-390 (2006).
42. 3 in various tissues. J. Steroid Biochem. Mol. Biol. 103 (3-5), 552-557 (2007).
43. Schauber J, Dorschner RA, Coda AB et al.: Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117 (3), 803-811 (2007).
44. Liu PT, Schenk M, Walker VP et al.: Convergence of IL-1β and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PIoS One 4 (6), e5810 (2009).
45. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEES Lett. 374 (1), 1-5 (1995).
46. Sorensen OE, Follin P, Johnsen AH et al.: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97 (12), 3951-3959 (2001).
47. Lehrer RI, Ganz T: Cathelicidins: a family of endogenous antimicrobial peptides. Curr. Opin. Hematol. 9 (1), 18-22 (2002).
48. Zanetti M, Gennaro R, Scocchi M, Skerlavaj B: Structure and biology of cathelicidins. Adv. Exp. Med. Biol. 479, 203-218 (2000).
49. Frohm Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun. 67 (5), 2561-2566 (1999).
50. Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37JhCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA 95 (16), 9541-9546 (1998).
51. Murakami M, Ohtake T, Dorschner RA, Gallo RL: Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J. Dent. Res. 81 (12), 845-850 (2002).
52. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL: Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol. 119 (5), 1090-1095 (2002).
53. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH: Fall-39, a putative human peptide antibiotic, is cysteinefree and expressed in bone marrow and testis. Proc. NatlAcad. Sci. USA 92 (1), 195-199 (1995).
54. Malm J, Sorensen O, Persson T et al.: The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attachec to spermatozoa. Infect. Immun. 68 (7), 4297-4302 (2000).
55. Hammami-Hamza S, Doussau M, Bernard J et al.: Cloning and sequencing of SOB3, a human gene coding for a sperm protein homologous to an antimicrobial protein and potentially involved in zona pellucida binding. Mol. Hum. Reprod. 7 (7), 625-632 (2001).
56. Andersson E, Sorensen OE, Frohm B, Borregaard N, Egesten A, Malm J: Isolation of human cationic antimicrobial protein-18 from seminal plasma and its association with prostasomes. Hum. Reprod. 17 (10), 2529-2534 (2002).
57. Agerberth B, Charo J, Werr J et al.: The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96 (9), 3086-3093 (2000).
58. Di Nardo A, Vitiello A, Gallo RL: Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170 (5), 2274-2278 (2003).
59. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N: The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90 (7), 2796-2803 (1997).
60. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al.: Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A Streptococcus. J. Invest. Dermatol. 117 (1), 91-97 (2001).
61. Ong PY, Ohtake T, Brandt C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347 (15), 1151-1160 (2002).
62. Frohm M, Agerberth B, Ahangari G et al.: The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272 (24), 15258-15263 (1997).
63. Nizet V, Ohtake T, Lauth X et al.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414 (6862), 454-457 (2001).
64. Chromek M, Slamova Z, Bergman P et al.: The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12 (6), 636-641 (2006).
65. Putsep K, Carlsson G, Boman HG, Andersson M: Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360 (9340), 1144-1149 (2002).
66. Gombart AF, Koeffler HP: Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor c/ebp (ε). Curr. Opin. Hematol. 9 (1), 36-42 (2002).
67. Yang YH, Zheng GG, Li G, Zhang B, Song YH, Wu KF: Expression of LL-37 /hCAP-18 gene in human leukemia cells. Leuk. Res. 27 (10), 947-950 (2003).
68. Ganz T: Defensins: antimicrobial peptides of vertebrates. C. R. Biol. 327 (6), 539-549 (2004).
69. Davies PD: A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle 66 (4), 301-306 (1985).
70. Wilkinson RJ, Llewelyn M, Toossi Z et al.: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in West London: a case-control study. Lancet 355 (9204), 618-621 (2000).
71. Nnoaham KE, Clarke A: Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int. J. Epidemiol. 37 (1), 113-119 (2008).
72. 3, γ-interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57 (1), 159-163 (1986).
73. Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179 (4), 2060-2063 (2007).
74. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ: Vitamin D in the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 103 (3-5), 793-798 (2007).
75. Nursyam EW, Amin Z, Rumende CM: The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38 (1), 3-5 (2006).
76. Morcos MM, Gabr AA, Samuel S et al.: Vitamin D administration to tuberculous children and its value. Boll. Chim. Farm. 137 (5), 157-164 (1998).
77. Martineau AR, Wilkinson RJ, Wilkinson KA et al.: A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Respir. Crit. Care Med. 176 (2), 208-213 (2007).
78. WejseC, Gomes VF, Rabna P et al.: Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 179 (9), 843-850 (2009).
79. Martineau AR, Nanzer AM, Satkunam KR et al.: Influence of a single oral dose of vitamin D (2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. Int. J. Tuberc. Lung Dis. 13 (1), 119-125 (2009).
80. Laaksi I, Ruohola JP, Tuohimaa P et al.: An association of serum vitamin D concentrations < 40 nmol/l with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 86 (3), 714-717 (2007).
81. Karatekin G, Kaya A, Salihoglu O, Balci H, Nuhoglu A: Association of subclinical vitamin D deficiency in newborns with acute lower respiratory infection and their mothers. Eur. J. Clin. Nutr. 63 (4), 473-477 (2009).
82. Walker VP, Modlin RL: The vitamin D connection to pediatric infections and immune function. Pediatr. Res. (2009) (Epub ahead of print).
83. Ginde AA, Mansbach JM, Camargo CA Jr: Vitamin D, respiratory infections, and asthma. Curr. Allergy Asthma Rep. 9 (1), 81-87 (2009).
84. Cannell JJ, Vieth R, Umhau JC et al.: Epidemic influenza and vitamin D. Epidemiol. Infect. 134 (6), 1129-1140 (2006).
85. Bodnar LM, Krohn MA, Simhan HN: Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J. Nutr. 139 (6), 1157-1161 (2009).
86. Villamor E: A potential role for vitamin D on HIV infection? Nutr. Rev. 64 (5 Pt 1), 226-233 (2006).
87. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW: Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol. 181 (10), 7090-7099 (2008).
88. Gombart AF, Saito T, Koeffler HP: Exapation of an ancient ALU short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics 10 (1), 321 (2009).
89. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF: Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect. Immun. 70 (2), 953-963 (2002).
90. Erdag G, Morgan JR: Interleukin-1α and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann. Surg. 235 (1), 113-124 (2002).
91. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N: Wound healing and expression of antimicrobial peptides /polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol. 170 (11), 5583-5589 (2003).
92. Schauber J, Svanholm C, Termen S et al.: Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 52 (5), 735-741 (2003).
93. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL: Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118 (4), 509-519 (2006).
94. Islam D, Bandholtz L, Nilsson J et al.: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat. Med. 7 (2), 180-185 (2001).
95. Chakraborty K, Ghosh S, Koley H et al.: Bacterial exotoxins downregulate cathelicidin (hCAP-18JLL-37) and human β-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol. 10 (12), 2520-2537 (2008).
96. Vieth R: What is the optimal vitamin D status for health? Prog. Biophys. Mol. Biol. 92 (1), 26-32 (2006).
97. Adams JS, Ren S, Liu PT et al.: Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 182 (7), 4289-4295 (2009).
98. Krutzik SR, Hewison M, Liu PT et al.: IL-15 links TLR2/l-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J. Immunol. 181 (10), 7115-7120 (2008).
99. Lande R, Gregorio J, Facchinetti V et al.: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (7162), 564-569 (2007).
100. Ganguly D, Chamilos G, Lande R et al.: Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206 (9), 1983-1994 (2009).
101. 3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J. Immunol. 181 (12), 8504-8512 (2008).
102. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity 21 (2), 241-254 (2004).
103. Kao CY, Chen Y, Thai P et al.: IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κb signaling pathways. J. Immunol. 173 (5), 3482-3491 (2004).
104. Peric M, Koglin S, Dombrowski Y et al.: Vitamin D analogs differentially control antimicrobial peptide/"Alarmin" expression in psoriasis. PIoS One 4 (7), e6340 (2009).
105. Buchau AS, Macleod DT, Morizane S, Kotol PF, Hata T, Gallo RL: Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes. J. Invest. Dermatol. 129 (9), 2148-2155 (2009).
106. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294 (5548), 1866-1870 (2001).
107. Schmidt DR, Mangelsdorf DJ: Nuclear receptors of the enteric tract: guarding the frontier. Nutr. Rev. 66 (10 Suppl. 2), S88-S97 (2008).
108. Makishima M, Okamoto AY, Repa JJ et al.: Identification of a nuclear receptor for bile acids. Science 284 (5418), 1362-1365 (1999).
109. Adachi R, Honma Y, Masuno H et al.: Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. 46 (1), 46-57 (2005).
110. Staudinger JL, Goodwin B, Jones SA et al.: The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98 (6), 3369-3374 (2001).
111. Xie W, Radominska-Pandya A, ShiY et al.: An essential role for nuclear receptors SXR /PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98 (6), 3375-3380 (2001).
112. Matsubara T, Yoshinari K, Aoyama K et al.: Role of vitamin D receptor in the lithocholic acid-mediated CYP3a induction in vitro and in vivo. DrugMetab. Dispos. 36 (10), 2058-2063 (2008).
113. 3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 328 (2), 564-570 (2009).
114. Lorenzo-Zuniga V, Bartoli R, Planas R et al.: Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37 (3), 551-557 (2003).
115. Inagaki T, Moschetta A, Lee YK et al.: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. USA 103 (10), 3920-3925 (2006).
116. D'aldebert E, Biyeyeme Bi Mve MJ, Mergey M et al.: Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136 (4), 1435-1443 (2009).
117. Schwab M, Reynders V, Shastri Y, Loitsch S, Stein J, Schroder O: Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol. Immunol. 44 (8), 2107-2114 (2007).
118. Jurutka PW, Bartik L, Whitfield GK et al.: Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J. Bone Miner. Res. 22 (Suppl. 2), V2-V10 (2007).
119. Jacobsen F, Mittler D, Hirsch T et al.: Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18 /LL-37 is effective for the treatment of burn wound infections. Gene Ther. 12 (20), 1494-1502 (2005).
120. Raqib R, Sarker P, Bergman P et al.: Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc. Natl Acad. Sci. USA 103 (24), 9178-9183 (2006).
121. Zasloff M: Inducing endogenous antimicrobial peptides to battle infections. Proc. Natl Acad. Sci. USA 103 (24), 8913-8914 (2006).
122. Gombart AF, Bhan I, BorregaardN et al.: Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin. Infect. Dis. 48 (4), 418-424 (2009).
123. Jeng L, Yamshchikov AV, Judd SE et al.: Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J. Transl. Med. 7, 28 (2009).
124. Hata TR, Kotol P, Jackson M et al.: Administration of oral vitamin D induces cathelicidin production in atopic individuals. J. Allergy Clin. Immunol. 122 (4), 829-831 (2008).
125. Oppenheim JJ, Tewary P, De La Rosa G, Yang D: Alarmins initiate host defense. Adv. Exp. Med. Biol. 601, 185-194 (2007).
126. Yang D, De La Rosa G, Tewary P, Oppenheim JJ: Alarmins link neutrophils and dendritic cells. Trends Immunol. (2009) (Epub ahead of print).
127. Nehring JA, Zierold C, Deluca HF: Lithocholic acid can carry out in vivo functions of vitamin D. Proc. NatlAcad. Sci. USA 104 (24), 10006-10009 (2007).
128. Ishizawa M, Matsunawa M, Adachi R et al.: Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J. Lpid Res. 49 (4), 763-772 (2008).
129. Holick MF: The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol. Aspects Med. 29 (6), 361-368 (2008).